Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Timeline

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 10, 2021 8:40pm

227 Views

Post# 33170925

RE:Timeline

StockingUp21 wrote:
Can please provide timeline for what is next.

Not pumper guessing and hoping. What timeline company has stated for next thing that can get out of these dumps.

Or does this matter because it is never on time

Stockingup ... go to the presentation and look at the final page (before the appendix) and look at the milestones. They are roughly in the order you should expect them - you add the dates where you think they will happen.

How's that for no pumping and no dumping ?

<< Previous

Bullboard Posts

Next >>

Dynamic Funds Launches new ETF series on the TSX